# Treatment outcomes of multidisciplinary management of recurrent urinary tract infections: A 2‐year experience in a dedicated complex‐UTI clinic

**Authors:** Pragnitha Chitteti, Ekpeno Inyang, Ahmed Ghonaimy, Jayne Morris‐Laverick, Stephanie Bezemer, Igor Kubelka, Victoria McCune, Mehwash Nadeem

PMC · DOI: 10.1002/bco2.70177 · 2026-03-04

## TL;DR

A specialized clinic using a team of experts improved treatment and quality of life for patients with recurring urinary tract infections.

## Contribution

Demonstrates the effectiveness of multidisciplinary care in managing complex recurrent UTIs through tailored interventions.

## Key findings

- 87.7% of patients achieved reduced UTI frequency or symptom resolution.
- 81% of patients reported good-to-excellent improvement in their symptoms.
- 70% of patients achieved good-to-excellent quality of life post-treatment.

## Abstract

This work aimed to assess treatment outcomes in patients with recurrent urinary tract infections (rUTIs) managed in a dedicated multidisciplinary complex‐UTI clinic. In addition, this work aimed to evaluate the impact of tailored interventions on patient‐reported outcomes, including quality of life (QoL) and symptomatic improvement.

A 2‐year, single‐centre, prospective observational cohort study was conducted in a dedicated tertiary care UTI clinic. A multidisciplinary team comprising urologists, microbiologists and specialist nurses developed individualized management plans based on thorough assessments, including patient history, physical examination and necessary investigations. Data variables included patient demographics, urine culture results with antibiotic sensitivities, investigations performed and the treatment options administered. The minimum follow‐up period was 6 months after the implementation of treatment in the clinic. Pretreatment and posttreatment QoL were assessed, along with posttreatment Patient Global Impression of Improvement (PGI‐I) scores.

A total of 211 patients (mean age: 58.3 years, 89.6% female) were included. First‐ and second‐line treatments were effective for 71% of patients, while 29% required tertiary interventions. Post‐treatment, 81% of patients reported good‐to‐excellent improvement on the PGI‐I scale, and 70% achieved good‐to‐excellent QoL. Overall treatment success, defined as reduced UTI frequency or symptom resolution, was reported in 87.7% of patients. Factors such as immunosuppression and history of hospital admission for urosepsis were associated with poor treatment outcomes with statistical significance.

Dedicated multidisciplinary UTI clinics significantly improve treatment outcomes and QoL for patients with rUTIs. The findings support broader adoption of multidisciplinary approaches, emphasizing early intervention and tailored care to optimize clinical efficiency and enhance the patient experience.

## Full-text entities

- **Diseases:** stroke (MESH:D020521), autoimmune diseases (MESH:D001327), renal mass (MESH:C536030), spinal cord injuries (MESH:D013119), pyelonephritis (MESH:D011704), MDR (MESH:D018088), Parkinson's disease (MESH:D010300), pain (MESH:D010146), angiomyolipoma (MESH:D018207), diabetes mellitus (MESH:D003920), malignancies (MESH:D009369), STI (MESH:D012749), neuropathic (MESH:D009437), bacterial infections (MESH:D001424), renal cysts (MESH:D003560), Prostate Symptom (MESH:D011472), bladder cancer (MESH:D001749), Neuropathy (MESH:D009422), multiple sclerosis (MESH:D009103), urethral stenosis (MESH:D014525), hypertension (MESH:D006973), Cystitis cystica (MESH:D016137), spina bifida (MESH:D016135), renal scarring (MESH:D005921), renal stones (MESH:D007669), UTIs (MESH:D014552), Infections (MESH:D007239)
- **Chemicals:** vitamin C (MESH:D001205), D-mannose (MESH:D008358), methenamine hippurate (MESH:C011481), methenamine (MESH:D008709), nitrofurantoin (MESH:D009582), glycosaminoglycan (MESH:D006025), hippurate (MESH:C030514)
- **Species:** Escherichia coli (E. coli, species) [taxon 562], Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12960744/full.md

---
Source: https://tomesphere.com/paper/PMC12960744